NCT01196390 2026-02-18
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
Clinical Trials
95 trialsNCT06964568 2026-02-10
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Fudan University
Phase 3 Recruiting
NCT04821778 2026-01-21
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT03161522 2025-10-23
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT01512589 2025-10-10
Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07000253 2025-06-02
OMEC-5
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2/3 Not yet recruiting
NCT01249352 2025-03-31
NICE
Eurofarma Laboratorios S.A.
Phase 2/3 Completed
NCT05191667 2025-02-13
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Suspended
NCT04278287 2024-12-13
Chemoradiotherapy in Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT06646588 2024-10-17
SJZ-RMEEC01
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT06558175 2024-08-16
REPAIR
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1 Not yet recruiting
NCT03641547 2024-07-18
CHARIOT
University of Oxford
Phase 1 Completed
NCT06464614 2024-06-18
Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.
The First Affiliated Hospital of Henan University of Science and Technology
Phase 2 Not yet recruiting
NCT03306901 2024-05-23
ASSURE
Samsung Medical Center
Phase NA Active not recruiting
NCT04207918 2024-05-16
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02556762 2024-02-06
SUMC-EC-002
Shantou University Medical College
Phase 3 Unknown
NCT02037048 2024-01-08
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Phase 2 Unknown
NCT06186609 2024-01-02
PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
Affiliated Hospital of Nantong University
Phase 2 Recruiting
NCT06061146 2023-12-26
TCRTOE
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT01307956 2023-10-26
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
University of Nebraska
Phase 2 Terminated
NCT02716688 2023-09-22
S-1 and Radiotherapy for Elderly Esophageal Cancer Patients
Zhejiang Provincial People's Hospital
Phase 2 Withdrawn
NCT03790553 2023-08-03
Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma
Fudan University
Phase 3 Unknown
NCT04764227 2023-08-03
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
Fudan University
Phase 2 Active not recruiting
NCT00551759 2023-07-03
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00033657 2023-06-28
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00318903 2023-05-25
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
University of Alabama at Birmingham
Phase 2 Completed
NCT01333033 2023-04-13
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT05800054 2023-04-05
Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase NA Recruiting
NCT03544736 2023-03-22
Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)
Oslo University Hospital
Phase 1/2 Active not recruiting
NCT00573131 2022-06-22
Efficacy and Safety of OncoGelâ„¢ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
Boston Scientific Corporation
Phase 2 Terminated
NCT00655876 2022-06-14
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00393068 2022-03-02
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00193128 2021-11-24
Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT01077999 2021-04-21
Chemoradiation and Panitumumab for Esophageal Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Completed
NCT01217060 2021-04-13
Trimodality Management of T1b Esophageal Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03936179 2021-03-18
High Dose PET/CT-guided Intensity Modulated Radiotherapy and Concurrent Chemotherapy in Esophageal Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase NA Unknown
NCT00006472 2020-08-18
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Medstar Health Research Institute
Phase 2 Terminated
NCT02403531 2020-06-02
Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer
Sun Yat-sen University
Phase 2 Completed
NCT01102088 2020-05-22
Simultaneous Integrated Boost (SIB) in Esophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00052910 2020-05-07
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00047112 2020-03-30
Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer
Federation Francophone de Cancerologie Digestive
Phase 3 Completed
NCT01787006 2020-03-10
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
University Hospital Schleswig-Holstein
Phase 2 Completed
NCT02241499 2020-02-28
PALAESTRA
Lund University Hospital
Phase 2 Completed
NCT02389751 2019-07-24
Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01915693 2019-06-04
ROCS
Velindre NHS Trust
Phase 3 Completed
NCT01372202 2019-01-25
J10130
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00493025 2018-12-06
Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02741856 2018-10-25
SCOPE2
Velindre NHS Trust
Phase 2/3 Unknown
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn